Selective Mediterranean Diet in Immune Thrombocytopenia

Sponsor
Assiut University
Study ID
NCT07798050
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Not accepted

Interventions

  • Selective Mediterranean Diet — BEHAVIORAL
    A selective Mediterranean diet regimen based on Mediterranean diet principles with stepwise elimination and reintroduction of certain foods, as an adjunct to standard pharmacological treatment for immune thrombocytopenia (ITP).
  • Standard Pharmacological Therapy for ITP — DRUG
    Standard pharmacological treatment for primary immune thrombocytopenia as prescribed by the treating physician, including corticosteroids (e.g., dexamethasone, prednisone) or intravenous immunoglobulin (IVIg), according to standard clinical guidelines.

Study Details

This randomized controlled trial aims to evaluate the effect of a selective Mediterranean diet regimen, used as an adjunct to standard therapy, on platelet count and bleeding-related outcomes in adult patients with primary immune thrombocytopenia (ITP).

Key Dates

First listed
Sep 1, 2026
Start date
Sep 1, 2026
Status verified
Aug 2026
Primary completion
Sep 1, 2027
Completion
Mar 25, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Mediterranean Diet + Standard Therapy
    Participants will follow a selective Mediterranean diet regimen in addition to their usual standard treatment for immune thrombocytopenia.
  • Active Comparator: Standard Therapy Only
    Participants will continue their usual standard pharmacological treatment for immune thrombocytopenia without dietary intervention.

Primary Outcome Measure

Change in platelet count [ Time Frame: Baseline and 12 weeks ]

Central Contacts

Related Studies